Gregory A. Daniels

17.7k total citations · 3 hit papers
116 papers, 6.0k citations indexed

About

Gregory A. Daniels is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Gregory A. Daniels has authored 116 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 33 papers in Immunology and 30 papers in Molecular Biology. Recurrent topics in Gregory A. Daniels's work include Cancer Immunotherapy and Biomarkers (49 papers), CAR-T cell therapy research (39 papers) and Immunotherapy and Immune Responses (29 papers). Gregory A. Daniels is often cited by papers focused on Cancer Immunotherapy and Biomarkers (49 papers), CAR-T cell therapy research (39 papers) and Immunotherapy and Immune Responses (29 papers). Gregory A. Daniels collaborates with scholars based in United States, Netherlands and Australia. Gregory A. Daniels's co-authors include Razelle Kurzrock, Lyudmila Bazhenova, Sandip Pravin Patel, Aaron M. Goodman, Shumei Kato, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Shujun Luo and Louise C. Laurent and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Gregory A. Daniels

115 papers receiving 5.9k citations

Hit Papers

Tumor Mutational Burden as an Independent Predictor of R... 2012 2026 2016 2021 2017 2012 2021 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
    2017 1.6k citations Aaron M. Goodman, Shumei Kato et al. Molecular Cancer Therapeutics profile →
  2. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells
    2012 1.2k citations Daniel Ramsköld, Shujun Luo et al. Nature Biotechnology profile →
  3. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
    2021 174 citations Assuntina G. Sacco, Ruifeng Chen et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregory A. Daniels United States 28 3.3k 2.4k 1.5k 1.5k 1.2k 116 6.0k
Isabelle Treilleux France 47 3.6k 1.1× 3.1k 1.3× 1.7k 1.1× 2.3k 1.6× 810 0.7× 219 7.9k
Stefano Indraccolo Italy 47 2.5k 0.8× 3.5k 1.5× 2.2k 1.4× 1.4k 0.9× 828 0.7× 209 7.0k
Josef Vormoor Germany 35 3.5k 1.1× 3.2k 1.4× 1.2k 0.8× 1.5k 1.0× 499 0.4× 117 7.8k
Hartmut Koeppen United States 30 3.0k 0.9× 3.5k 1.5× 992 0.6× 1.9k 1.3× 583 0.5× 62 6.4k
Tsukasa Shibue United States 20 3.6k 1.1× 4.6k 1.9× 1.7k 1.1× 1.1k 0.7× 589 0.5× 28 7.2k
Marc‐Henri Stern France 43 2.4k 0.7× 3.5k 1.5× 2.1k 1.3× 1.2k 0.8× 896 0.8× 149 6.5k
Patrizia Nanni Italy 48 2.5k 0.8× 2.8k 1.2× 813 0.5× 2.6k 1.8× 1.1k 1.0× 171 6.5k
Otávia L. Caballero United States 38 3.1k 1.0× 4.9k 2.1× 1.4k 0.9× 2.8k 1.9× 615 0.5× 74 7.9k
Rajmohan Murali United States 51 4.3k 1.3× 3.1k 1.3× 1.6k 1.0× 1.2k 0.8× 2.2k 1.8× 179 8.5k
Göran Jönsson Sweden 38 2.2k 0.7× 2.5k 1.1× 1.2k 0.8× 1.1k 0.8× 630 0.5× 118 4.7k

Countries citing papers authored by Gregory A. Daniels

Since Specialization
Citations

This map shows the geographic impact of Gregory A. Daniels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory A. Daniels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory A. Daniels more than expected).

Fields of papers citing papers by Gregory A. Daniels

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory A. Daniels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory A. Daniels. The network helps show where Gregory A. Daniels may publish in the future.

Co-authorship network of co-authors of Gregory A. Daniels

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory A. Daniels. A scholar is included among the top collaborators of Gregory A. Daniels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory A. Daniels. Gregory A. Daniels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Botta, Gregory P., Joseph Chao, H. Ma, et al.. (2024). Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells. Journal for ImmunoTherapy of Cancer. 12(2). e007927–e007927. 15 indexed citations
2.
3.
Migden, Michael R., Wanxing Chai‐Ho, Gregory A. Daniels, et al.. (2023). 777 Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS). SHILAP Revista de lepidopterología. A874–A874. 1 indexed citations
4.
Davar, Diwakar, Alexandra P. Ikeguchi, Elizabeth I. Buchbinder, et al.. (2023). A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).. Journal of Clinical Oncology. 41(16_suppl). TPS9594–TPS9594. 4 indexed citations
5.
Lin, Andrew, Soo J. Park, Gregory A. Daniels, & Shyamanga Borooah. (2023). Pigmentary retinopathy associated with immune therapy for advanced cutaneous melanoma. American Journal of Ophthalmology Case Reports. 30. 101849–101849. 3 indexed citations
6.
Milton, Denái R., William H. Sharfman, Bret Taback, et al.. (2021). An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. OncoImmunology. 10(1). 1984059–1984059. 5 indexed citations
7.
Jensen, Taylor J., Aaron M. Goodman, Christopher K. Ellison, et al.. (2021). Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible. Molecular Cancer Therapeutics. 20(11). 2274–2279. 7 indexed citations
8.
9.
Sacco, Assuntina G., Ruifeng Chen, Francis P. Worden, et al.. (2021). Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. The Lancet Oncology. 22(6). 883–892. 174 indexed citations breakdown →
10.
Daniels, Gregory A., Sandip Pravin Patel, Assuntina G. Sacco, et al.. (2020). Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. Translational Cancer Research. 9(1). 203–209. 24 indexed citations
11.
Goodman, Aaron M., Shumei Kato, Ranajoy Chattopadhyay, et al.. (2019). Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunology Research. 7(6). 866–873. 22 indexed citations
12.
Ribas, Antoni, Theresa Medina, Shivaani Kummar, et al.. (2018). SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discovery. 8(10). 1250–1257. 237 indexed citations
13.
Jensen, Taylor J., Aaron M. Goodman, Shumei Kato, et al.. (2018). Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Molecular Cancer Therapeutics. 18(2). 448–458. 67 indexed citations
14.
Goodman, Aaron M., Shumei Kato, Lyudmila Bazhenova, et al.. (2017). Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Molecular Cancer Therapeutics. 16(11). 2598–2608. 1638 indexed citations breakdown →
15.
Goodman, Aaron M., Gregory A. Daniels, Sandip Pravin Patel, et al.. (2017). Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy. Clinical Cancer Research. 23(19). 5729–5736. 159 indexed citations
16.
Curti, Brendan D., Gregory A. Daniels, David F. McDermott, et al.. (2017). Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. Journal for ImmunoTherapy of Cancer. 5(1). 102–102. 27 indexed citations
17.
Schwaederlé, Maria, Barbara A. Parker, Richard B. Schwab, et al.. (2016). Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Molecular Cancer Therapeutics. 15(4). 743–752. 125 indexed citations
18.
Sznol, Mario, Pier Francesco Ferrucci, David Hogg, et al.. (2016). Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL). Annals of Oncology. 27. vi385–vi385. 2 indexed citations
19.
Ramsköld, Daniel, Shujun Luo, Yu-Chieh Wang, et al.. (2012). Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nature Biotechnology. 30(8). 777–782. 1174 indexed citations breakdown →
20.
Daniels, Gregory A. & Michael R. Lieber. (1996). Transcription Targets Recombination at Immunoglobulin Switch Sequences in a Strand-Specific Manner. Current topics in microbiology and immunology. 217. 171–189. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isabelle Treilleux Breakdown of academic impact, for papers by Stefano Indraccolo Breakdown of academic impact, for papers by Josef Vormoor Breakdown of academic impact, for papers by Hartmut Koeppen Breakdown of academic impact, for papers by Tsukasa Shibue Breakdown of academic impact, for papers by Marc‐Henri Stern Breakdown of academic impact, for papers by Patrizia Nanni Breakdown of academic impact, for papers by Otávia L. Caballero Breakdown of academic impact, for papers by Rajmohan Murali Breakdown of academic impact, for papers by Göran Jönsson
Rankless by CCL
2026